IDDF2019-ABS-0191 Initial experience of faecal microbiota transplantation with frozen stools for the treatment of recurrent or refractory clostridioides difficile infection – a retrospective review from a quaternary referral centre in hong kong

Rashid N. Lui, Louis Ho Shing Lau, Ting Ting Chan, Sunny H. Wong, Kitty Cheung, Amy Li, Ml Chin, Whitney Tang, Jessica Y. L. Ching, Kelvin Lam, Paul Chan, Justin C. Wu, Joseph J.�y. Sung, Francis K.l. Chan, Siew CngClinical 2019 · DOI

Abstract

Clostridioides difficile infection (CDI) is a major cause of nosocomial infection, leading to significant morbidity and mortality. While Faecal Microbiota Transplantation (FMT) is a promising option for recurrent and refractory CDI, the logistics of fresh stool preparation can be challenging. This study evaluates the safety, efficacy, and feasibility of using frozen stools from a newly established biobank in Hong Kong. In a retrospective review of 19 patients, frozen FMT achieved an 84.2% cure rate with an excellent safety profile, demonstrating its potential as a standard clinical intervention.

Introduction

Clostridioides difficile infection (CDI) represents a significant burden in healthcare settings, typically occurring after antibiotic use disrupts the natural balance of the gut microbiome. For patients with recurrent or refractory CDI, standard antibiotic treatments often fail, leading to chronic diarrhea, dehydration, and high mortality rates—particularly among elderly and frail populations.

Faecal Microbiota Transplantation (FMT) has emerged as a "gold standard" for restoring gut health by transferring stool from a healthy donor to a patient. However, using fresh stool is logistically difficult, requiring immediate processing and donor availability on short notice. To address these challenges, the Chinese University of Hong Kong (CUHK) established a stool biobank. This paper reviews the first major experience in Hong Kong using frozen stools for FMT in a quaternary referral centre.

Methods

The researchers conducted a retrospective, single-centre study of 19 consecutive patients treated for recurrent or refractory CDI using frozen stools from 2017 to the present.

Key Study Parameters: * Patient Cohort: 19 patients with a median age of 70 years (IQR 58.5–77.5). The group was medically fragile; nearly half were bedridden or chair-bound, and over 80% had recent hospitalizations or were residents of long-term care facilities. * Delivery Routes: FMT was administered via esophagogastroduodenoscopy (OGD) in 12 patients (63.2%), colonoscopy in 6 (31.6%), and feeding tube in 1 (5.3%). * Outcome Measures: The primary endpoint was the resolution of diarrhea without relapse within 8 weeks. Safety and clinical demographics were collected from the Hospital Authority’s Clinical Management System.

Results

The study yielded highly positive results, confirming the efficacy of frozen microbiota:

  • Clinical Success: 16 out of 19 patients (84.2%) achieved full resolution of symptoms without relapse within the 8-week follow-up period.
  • Safety Profile: The procedure was generally well-tolerated. No serious adverse events were attributable to the FMT itself.
  • Minor Complications: Reported side effects were mild and transient, including abdominal pain (15.8%) and bloating (5.3%).

These results are consistent with international literature regarding fresh stool FMT, suggesting that the freezing process does not diminish the therapeutic potency of the donor microbiota.

Discussion

The transition from fresh to frozen stool is a significant logistical advancement for hospital workflows. It allows for rigorous, pre-emptive donor screening for pathogens (such as HIV, Hepatitis, and multi-drug resistant organisms), ensuring a safe, "off-the-shelf" treatment option is available when needed.

One of the most striking insights is the high efficacy (84.2%) maintained despite the poor functional status of the cohort. The successful use of the "upper route" (OGD) for the majority of patients also suggests that less invasive delivery methods are effective, which is particularly beneficial for elderly patients who may not tolerate a full colonoscopy.

Limitations and Future Directions

As a retrospective study with a small sample size (n=19), these findings serve as a proof-of-concept for the region. The reliance on existing medical records may also lead to the under-reporting of minor side effects compared to prospective trials. Future efforts should focus on raising clinician awareness to ensure FMT is used earlier in the treatment cycle for difficult-to-treat cases.

Conclusion

This study reports the largest case series of frozen stool FMT in Hong Kong, showing it to be a safe, efficacious, and logistically feasible intervention. The success of the CUHK stool biobank provides a model for expanding FMT access across other regions in Asia, potentially improving outcomes for high-risk CDI patients.

Reference: Lui R, et al. (2019). IDDF2019-ABS-0191 Initial experience of faecal microbiota transplantation with frozen stools for the treatment of recurrent or refractory clostridioides difficile infection. Gut, 68(Suppl 1):A100.

Summary updated

Abstract

<h3>Background</h3> <i>Clostridioides difficile</i> infection (CDI) is a major cause of nosocomial infection leading to significant morbidity and mortality. Faecal microbiota transplantation (FMT) has emerged as a promising option for recurrent and refractory CDI. This study aims to assess the safety, efficacy and feasibility of FMT using frozen stools from a newly established stool biobank for the treatment of CDI in Hong Kong. <h3>Methods</h3> We conducted a single-centre, retrospective study for all consecutive cases of recurrent/refractory CDI who had FMT with frozen stools performed from 2017 to present. Clinical demographics, outcome, and safety parameters were collected from the Clinical Management System of the Hospital Authority, Hong Kong or from the review of case notes. <h3>Results</h3> A total of 19 patients with recurrent or refractory CDI and FMT performed using frozen stools from the CUHK stool biobank were identified [median age 70 years (interquartile range of 58.5 - 77.5 years); 68.4% males]. Almost half of the cases were in a bedridden or chair-bound state, a surrogate of a poor functional status. The majority (&gt; 80%) of patients were hospitalized within the recent 3 months or were long-term care facility residents. FMT was delivered via feeding tube in 1 (5.3%), esophagogastroduodenoscopy (OGD) in 12 (63.2%), or colonoscopy in 6 (31.6%) of the patients. Resolution of diarrhoea without relapse within 8 weeks was achieved in 16 out of 19 patients (84.2%). The procedure was generally well tolerated with no serious adverse events attributable to FMT. The most common complication after FMT was abdominal pain (n = 3, 15.8%). Bloating was reported in 1 patient (5.3%). These results suggest that the cure rates of FMT using frozen stools for recurrent or refractory CDI were comparable with those reported in the literature with an excellent safety profile. <h3>Conclusions</h3> We report the largest case series of FMT using frozen stools to treat refractory or recurrent CDI in Hong Kong, showing that it is a safe, efficacious and feasible intervention. Efforts should be made to raise the awareness of this important treatment, with earlier use in difficult-to-treat cases.
BibTeX
@inproceedings{lui2019iddf,
  author = {Rashid N. Lui and Louis Ho Shing Lau and Ting Ting Chan and Sunny H. Wong and Kitty Cheung and Amy Li and ML Chin and Whitney Tang and Jessica Y. L. Ching and Kelvin Lam and Paul Chan and Justin C. Wu and Joseph J.�Y. Sung and Francis K.L. Chan and Siew CNG},
  title = {{IDDF2019-ABS-0191 Initial experience of faecal microbiota transplantation with frozen stools for the treatment of recurrent or refractory clostridioides difficile infection – a retrospective review from a quaternary referral centre in hong kong}},
  booktitle = {Clinical},
  year = {2019},
  doi = {10.1136/gutjnl-2019-iddfabstracts.189},
}
Figure